This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Tempus Labs, Inc.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Gary Palmer: Innovator in Breast Cancer Diagnostics
Introduction
Gary Palmer is a notable inventor based in Chicago, IL (US). He has made significant contributions to the field of breast cancer diagnostics through his innovative work. His research focuses on utilizing real-world evidence to improve diagnostic testing and treatment patterns for breast cancer patients.
Latest Patents
Gary Palmer holds a patent titled "Real-world evidence of diagnostic testing and treatment patterns in U.S. breast cancer patients with implications for treatment biomarkers from RNA-sequencing data." This patent presents techniques for replacing image assays with real-world data and RNA-seq analysis. The methods aim to assess biological pathways for identifying molecular subtypes. Additionally, the systems described in the patent diagnose HER2 status for patients by identifying discordant HER2 status results between immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH), as well as through gene expression data.
Career Highlights
Gary Palmer is currently employed at Tempus Labs, Inc., where he continues to advance his research in the field of oncology. His work is instrumental in bridging the gap between laboratory findings and real-world applications in breast cancer treatment.
Collaborations
Some of his notable coworkers include Louis Fernandes and Caroline Epstein, who contribute to the collaborative efforts at Tempus Labs, Inc. Their combined expertise enhances the research and development of innovative diagnostic solutions.
Conclusion
Gary Palmer's contributions to breast cancer diagnostics through his patent and work at Tempus Labs, Inc. highlight the importance of real-world evidence in improving patient outcomes. His innovative techniques pave the way for more accurate and effective diagnostic methods in oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
